Krebs Biochemicals & IND

Krebs Biochemicals & Ind (KREBSBIO) is a micro-cap Healthcare company valued at ₹130 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Krebs Biochemicals & Ind last traded at ₹60.8, modestly down 0.03% on the day.

Recent developments

2026-06-30: The company reported a net loss of ₹17 crore for the fiscal year ending March 2026, showing a narrowing loss compared to the previous year. 2026-06-30: The latest quarter ended with a net loss of ₹2 crore, down from ₹5 crore in the same quarter a year earlier.

Financial performance

The company's business is shrinking, with annual revenue falling 44.8% year-over-year. The latest quarter saw revenue rise 27.4% compared to the same quarter a year earlier, but net profit remained a loss, narrowing from ₹5 crore to ₹2 crore. Margins have worsened, with the net profit margin dropping 8.6 percentage points to -71.4%.

Valuation multiples

A price-to-earnings ratio is not meaningful here because the company is loss-making; the stock trades at -0.82 times book value.

Things to watch

The company has reported a net loss of ₹17 crore for the latest fiscal year, with the net profit margin worsening to -71.4%. Revenue has declined sharply over the past three years, with a compound annual growth rate of -23.0%. The stock is 11.5% below its 52-week high.

Where it stands

Krebs Biochemicals & Industries Ltd ended the latest fiscal year with a net loss of ₹17 crore, showing some improvement compared to the previous year. The stock is 11.5% below its 52-week high, and revenue has declined sharply over the past three years. The most significant figure is the net loss of ₹17 crore for the latest fiscal year.

Summarised by DocStoX's model on 2026-10-04 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.